161 related articles for article (PubMed ID: 22867774)
1. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.
Griffiths RI; Gleeson ML; Danese MD; O'Hagan A
Value Health; 2012; 15(5):656-63. PubMed ID: 22867774
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal analysis of censored medical cost data.
Başer O; Gardiner JC; Bradley CJ; Yüce H; Given C
Health Econ; 2006 May; 15(5):513-25. PubMed ID: 16389670
[TBL] [Abstract][Full Text] [Related]
3. Estimating lifetime or episode-of-illness costs under censoring.
Basu A; Manning WG
Health Econ; 2010 Sep; 19(9):1010-28. PubMed ID: 20665908
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer.
Sail KR; Franzini L; Lairson DR; Du XL
Value Health; 2012 Jan; 15(1):72-80. PubMed ID: 22264974
[TBL] [Abstract][Full Text] [Related]
5. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
6. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Sorensen SV; Goh JW; Pan F; Chen C; Yardley D; Martín M; Knopf K; Benedict A; Giorgetti C; Iyer S
Int J Technol Assess Health Care; 2012 Jan; 28(1):12-21. PubMed ID: 22617734
[TBL] [Abstract][Full Text] [Related]
7. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract][Full Text] [Related]
8. A two-part model for censored medical cost data.
Tian L; Huang J
Stat Med; 2007 Oct; 26(23):4273-92. PubMed ID: 17330248
[TBL] [Abstract][Full Text] [Related]
9. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
[TBL] [Abstract][Full Text] [Related]
10. Measuring costs: administrative claims data, clinical trials, and beyond.
Etzioni R; Riley GF; Ramsey SD; Brown M
Med Care; 2002 Jun; 40(6 Suppl):III63-72. PubMed ID: 12064760
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
12. An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population.
Hadley J; Polsky D; Mandelblatt JS; Mitchell JM; Weeks JC; Wang Q; Hwang YT;
Health Econ; 2003 Mar; 12(3):171-86. PubMed ID: 12605463
[TBL] [Abstract][Full Text] [Related]
13. Regression analysis of incomplete medical cost data.
Lin DY
Stat Med; 2003 Apr; 22(7):1181-200. PubMed ID: 12652561
[TBL] [Abstract][Full Text] [Related]
14. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.
Stokes ME; Thompson D; Montoya EL; Weinstein MC; Winer EP; Earle CC
Value Health; 2008; 11(2):213-20. PubMed ID: 18380633
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
16. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy.
Heck JE; Albert SM; Franco R; Gorin SS
J Am Geriatr Soc; 2008 Sep; 56(9):1687-92. PubMed ID: 18691280
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
19. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
20. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
